UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 33

Sortiert nach

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Investigational new drugs, 2020-10, Vol.38 (5), p.1570-1579

2020

Volltextzugriff (PDF)

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Liver international, 2019-08, Vol.39 (8), p.1468-1477

2019

Volltextzugriff (PDF)

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Journal of pharmacokinetics and pharmacodynamics, 2010-02, Vol.37 (1), p.3-24

2010

Volltextzugriff (PDF)

Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs

Journal of pharmacokinetics and pharmacodynamics, 2007-06, Vol.34 (3), p.313-331

2007

Volltextzugriff (PDF)

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Clinical pharmacology and therapeutics, 2023-06, Vol.113 (6), p.1258-1267

2023

Volltextzugriff (PDF)

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Alzheimer's & dementia, 2023-06, Vol.19 (S7), p.n/a

2023

Volltextzugriff (PDF)

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer

European journal of cancer (1990), 2016-10, Vol.66, p.95-103

2016

Volltextzugriff (PDF)

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Alzheimer's & dementia, 2023-06, Vol.19 (6), p.2253-2264

2023

Volltextzugriff (PDF)

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2015-12, Vol.76 (6), p.1143-1152

2015

Volltextzugriff (PDF)

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Alzheimer's & dementia, 2023-12, Vol.19 (S14), p.n/a

2023

Volltextzugriff (PDF)

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

Pharmaceutical research, 2014-10, Vol.31 (10), p.2829-2843

2014

Volltextzugriff (PDF)

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.673-680

2017

Volltextzugriff (PDF)

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Journal of pharmacokinetics and pharmacodynamics, 2004-06, Vol.31 (3), p.185-213

2004

Volltextzugriff (PDF)

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Investigational new drugs, 2015-04, Vol.33 (2), p.357-370

2015

Volltextzugriff (PDF)

Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer

Cancer chemotherapy and pharmacology, 2019-11, Vol.84 (5), p.1003-1015

2019

Volltextzugriff (PDF)

Mechanism for Enhanced Absorption of a Solid Dispersion Formulation of LY2300559 Using the Artificial Stomach Duodenum Model

Molecular pharmaceutics, 2015-04, Vol.12 (4), p.1131-1140

2015

Volltextzugriff (PDF)

Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9

Journal of pharmacokinetics and pharmacodynamics, 2012-04, Vol.39 (2), p.147-160

2012

Volltextzugriff (PDF)

A phase 1 study of anti-TGF[beta] receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Cancer chemotherapy and pharmacology, 2017-04, Vol.79 (4), p.673

2017

Volltextzugriff (PDF)

A program for individual and population optimal design for univariate and multivariate response pharmacokinetic–pharmacodynamic models

Computer methods and programs in biomedicine, 2007-04, Vol.86 (1), p.51-61

2007

Volltextzugriff (PDF)

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

European journal of clinical pharmacology, 2007-05, Vol.63 (5), p.485-498

2007

Volltextzugriff (PDF)

Diazepam pharamacokinetics from preclinical to phase I using a bayesian population physiologically based pharmacokinetic model with informative prior distributions in winbugs

Journal of pharmacokinetics and pharmacodynamics, 2006-10, Vol.33 (5), p.571-594

2006

Volltextzugriff (PDF)

Cardiac Safety of TGF-[beta] Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Cardiovascular toxicology, 2015-10, Vol.15 (4), p.309

2015

Volltextzugriff (PDF)

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-[beta] receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Investigational new drugs, 2015-04, Vol.33 (2), p.357

2015

Volltextzugriff (PDF)

The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments

Computer methods and programs in biomedicine, 2005-11, Vol.80 (2), p.115-125

2005

Volltextzugriff (PDF)

Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis : diazepam case study

Journal of pharmacokinetics and pharmacodynamics, 2006-02, Vol.33 (1), p.1-27

2006

Volltextzugriff (PDF)

1 – 25 von 33

Suche als RSS-Feed

Aktive Filter

KollektionEZB Electronic Journals Library

Zeitschrift / SerieCancer Research

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(32)
Mit Volltextzugriff
(31)

Publikationsform

Artikel
(32)
Dissertationen
(1)

Sprache

Englisch
(33)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

Ethnic differences in the population pharmacokinetics and pharmacodynamics of warfarin

Optimal design for multiresponse pharmacokinetic-pharmacodynamic models - dealing with unbalanced designs

Donanemab Population Pharmacokinetics, Amyloid Plaque Reduction, and Safety in Participants with Alzheimer's Disease

Donanemab exposure‐efficacy relationship in patients with early symptomatic Alzheimer’s disease

Early change in tumour size predicts overall survival in patients with first-line metastatic breast cancer

Disease progression model using the integrated Alzheimer's Disease Rating Scale

Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials

Handling Missing Data in a Duloxetine Population Pharmacokinetic/Pharmacodynamic Model – Imputation Methods and Selection Models

A phase 1 study of anti-TGFβ receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

Fuzzy simulation of pharmacokinetic models: Case study of whole body physiologically based model of diazepam

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

Population pharmacokinetics and exposure–overall survival analysis of the transforming growth factor-β inhibitor galunisertib in patients with pancreatic cancer

Mechanism for Enhanced Absorption of a Solid Dispersion Formulation of LY2300559 Using the Artificial Stomach Duodenum Model

Population pharmacokinetic modelling of S-warfarin to evaluate the design of drug–drug interaction studies for CYP2C9

A phase 1 study of anti-TGF[beta] receptor type-II monoclonal antibody LY3022859 in patients with advanced solid tumors

A program for individual and population optimal design for univariate and multivariate response pharmacokinetic–pharmacodynamic models

Linking preclinical and clinical whole-body physiologically based pharmacokinetic models with prior distributions in NONMEM

Diazepam pharamacokinetics from preclinical to phase I using a bayesian population physiologically based pharmacokinetic model with informative prior distributions in winbugs

Cardiac Safety of TGF-[beta] Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study

Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-[beta] receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer

The use of a modified Fedorov exchange algorithm to optimise sampling times for population pharmacokinetic experiments

Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis : diazepam case study

Aktive Filter

Suchergebnisse filtern